Harm van Tinteren

Active 1971–2025

143
Papers
27,358
Citations
89
h-index
140
i10-index

Citations

Citations per year for Harm van Tinteren1971: 1 citations1973: 1 citations1982: 2 citations1983: 2 citations1984: 1 citations1985: 1 citations1989: 1 citations1990: 1 citations1991: 1 citations1992: 1 citations1993: 3 citations1994: 15 citations1995: 20 citations1996: 12 citations1997: 25 citations1998: 24 citations1999: 28 citations2000: 28 citations2001: 39 citations2002: 41 citations2003: 64 citations2004: 110 citations2005: 84 citations2006: 121 citations2007: 113 citations2008: 126 citations2009: 108 citations2010: 129 citations2011: 135 citations2012: 143 citations2013: 154 citations2014: 131 citations2015: 147 citations2016: 170 citations2017: 191 citations2018: 174 citations2019: 783 citations2020: 1,013 citations2021: 943 citations2022: 719 citations2023: 621 citations2024: 909 citations2025: 434 citations2026: 9 citations1972: no citations, so this year is not shown1974–1981: no citations, so these years are not shown1986–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,651 citing papers, 22.2% of this breakdownNetherlands: 1,102 citing papers, 9.2% of this breakdownChina: 895 citing papers, 7.5% of this breakdownUnited Kingdom: 734 citing papers, 6.2% of this breakdownGermany: 727 citing papers, 6.1% of this breakdownItaly: 699 citing papers, 5.9% of this breakdownFrance: 600 citing papers, 5% of this breakdownSpain: 381 citing papers, 3.2% of this breakdownAustralia: 377 citing papers, 3.2% of this breakdownCanada: 372 citing papers, 3.1% of this breakdownBelgium: 347 citing papers, 2.9% of this breakdownSwitzerland: 295 citing papers, 2.5% of this breakdown
0%22.2%Other 23%

Fields

  • Medicine71.3%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology3.8%
  • Engineering1.3%
  • Computer Science0.8%
  • Materials Science0.5%
  • Other1.4%

Topics

  • Cancer Immunotherapy and Biomarkers6.4%
  • Intraperitoneal and Appendiceal Malignancies3.7%
  • Immunotherapy and Immune Responses3.5%
  • CAR-T cell therapy research2.6%
  • Cancer Genomics and Diagnostics2.6%
  • Ovarian cancer diagnosis and treatment2.6%
  • Other78.6%

Coauthors

All papers

Open in search
  1. AACR Project GENIE: Powering Precision Medicine through an International Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefèbvre, Michele L. Lenoue-Newton, Eva M. Lepisto, Mia Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric‐Bernstam, Christine Micheel, Clinton Miller, Gordon B. Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie Stickle, Thomas Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura van ‘t Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy Lu Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang - Cancer Discovery 2017 cited by 2,004

  2. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A. M. Stevense‐den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan‐Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers‐Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebæk, Lisbet Rosenkrantz Hölmich, Alexander C. J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, A. Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen - New England Journal of Medicine 2022 cited by 536

  3. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabine C. Linn, Ton N. Schumacher, Christian U. Blank, Marleen Kok - Nature Medicine 2019 cited by 889

  4. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 855

  5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,409

  6. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Winan J. van Houdt, Daniel S. Peeper, Andrew J. Spillane, Johan Hansson, Ton N. Schumacher, Georgina V. Long, Christian U. Blank - The Lancet Oncology 2019 cited by 522

  7. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Toru Watanabe, Greg Yothers, Ke‐Da Yu, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Lui, Zulian Lui, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Aman U. Buzdar, Vera J. Suman, Kelly K. Hunt, Robert Leonard, Janine Mansi, Catherine Delbaldo, Pascal Piedbois, Emmanuel Quinaux, Christian Fesl, Michael Gnant, Lidija Sölkner, Guenther G. Steger, Hans Petter Eikesdal, Per Eystein Lønning, Valerie Bée, Helena Fung, John R. Mackey, Miguel Martín, Michael F. Press, Evandro de Azambuja, Richard D. Gelber, Meredith M. Regan, Angelo Di Leo, Veerle Van Dooren, J.-M. Nogaret, John M.S. Bartlett, Bingshu E. Chen, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Kathleen I. Pritchard, Lois E. Shepherd, Donald A. Berry, Constance Cirrincione, Lawrence N. Shulman, Eric P. Winer, Rebecca Gelman, Jay R. Harris, Craig Henderson, Charles L. Shapiro, Peer Christiansen, Marianne Ewertz, Henning T. Mouridsen, Elise Van Leeuwen, Sabine C. Linn, Annelot G.J. van Rossum, Harm van Tinteren and 136 more - The Lancet 2023 cited by 189

  8. Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

    Authors: , , , , , , - Journal of Clinical Oncology 2003 cited by 2,027

  9. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

    Authors: , , , , , , , , - The Lancet 2014 cited by 592

  10. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joost Huiskens, Harm van Tinteren, Cornelis H.C. Dejong, Dirk J. Grünhagen, Gijs A. Patijn, Theo J. M. Ruers, T. Chapelle, John J. Hermans, Wouter K. G. Leclercq, Liselot Valkenburg‐van Iersel, Cecile Grootscholten, Joyce M. van Dodewaard-de Jong, Jeroen Vincent, Danny Houtsma, Maartje Los, Marien den Boer, Marija Trajkovic-Vidakovic, Theo van Voorthuizen, Miriam Koopman, Johanneke H.M.J.V. Vestjens, Hans Torrenga, Leonie J. Mekenkamp, G.J. Veldhuis, Marco B. Polée, Serge E. Dohmen, Heidi Schut, Annelie J.E. Vulink, Henk K. van Halteren, Jamal Oulad Hadj, Pieter-Paul J.B.M. Schiphorst, Ronald Hoekstra - The Lancet Oncology 2023 cited by 168

  11. 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

    Authors: , , , , - Annals of Surgical Oncology 2008 cited by 1,025

  12. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 85

  13. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Danny Houtsma, Johanna EA Portielje, R.J.B. Blaisse, Ernst Jan Spillenaar Bilgen, Marco B. Polée, Maud M. Geenen, Jeffrey P. B. M. Braak, Karen J. Neelis, Marije Slingerland, Rob LH Jansen, Jeroen Buijsen, Aart Beeker, Q. A. J. Eijsbouts, Johanna MGH van Riel, Tom Rozema, Dick Johan van Spronsen, Jetske M. Meerum Terwogt, Bea C. Tanis, Adelheid ME Van der Torren-Conze, Richard van Hilligersberg, Miriam Koopman, Marien O. den Boer, Geert‐Jan Creemers, Maurice J.C. van der Sangen, Marjolein EM Rentinck, H. Pieter van den Berg, G. J. P. M. Jonkers, D.A.R.H. Grootenboers, Annelie JE Vulink, Sjoerd Hovenga, Huub CJ Van der Mijle, Arnold Baars, A. Haringhuizen, Marije IE Appels, Ron C. Rietbroek, Ellen M. Hendriksen, Marie-Cecile Legdeur, Daan ten Bokkel Huinink, O Aart Van Dobbenburgh, Jitty M. Smit, Aart van Bochove, Gerrit-Jan Veldhuis, E.W. Muller, Johannes J. Bonenkamp, Pètra M. Braam, Jaap de Boer, Henk K. van Halteren, F.A.A. Valster, Alex L.T. Imholz, Marjan A. van Dijk, Ate van der Gaast, J (Hans)-Martin MB Otten, Heleen M. Ceha, Bengt Glimelius, Cecillia Lagerbäck, Mats Perman, Anders Johnsson, David Borg, Niels Hilmer Nielsen, Andrzej Piwowar, Mattias Elmlund, Helene Hörberg, Per Edlund, Bengt Johansson, Petra Flygare, Marie Louise Jespersen - The Lancet Oncology 2018 cited by 576

  14. Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients

    Authors: , , , , , , , , , - Annals of Surgery 2014 cited by 423

  15. Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675)

    Authors: , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 cited by 147

  16. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - BMC Cancer 2019 cited by 114

  17. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2015 cited by 528

  18. Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Norbert Graf, Roland Eils, Stefan M. Pfister, Marcel Kool, Manfred Gessler - Cancer Cell 2015 cited by 307

  19. Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Urology 2017 cited by 377

  20. Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

    Authors: , , , , , , , , , , , , , , , , , - Melanoma Research 2020 cited by 52

  21. Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 31

  22. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

    Authors: , , , , , , , , , , , , , , , , , , , - Haematologica 2020 cited by 102

  23. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

    Authors: , , , , , , , , , , , - The Lancet 1999 cited by 503

  24. Clinical Prediction Model To Characterize Pulmonary Nodules

    Authors: , , , , , , - CHEST Journal 2005 cited by 392